Skip to main content
Explore URMC

Wilmot Cancer Institute Logo

Paul M. Barr, M.D.
Paul M. Barr, M.D.

Paul M. Barr, M.D.

Medicine — Hematology/Oncology — Medical Oncology

Accepting New Patients

Paul M. Barr, M.D.

Medicine — Hematology/Oncology — Medical Oncology

Accepting New Patients


James P. Wilmot Cancer Center
601 Elmwood Ave.
Rochester, NY 14642
Get Directions



(585) 275-5823



(585) 273-1042

About Me

As the Director of the Clinical Trials Office for Wilmot Cancer Institute, I oversee our state-of-the-art clinical trials while also educating my patients about their disease so they are as informed as possible. This enables my patients to participate in the process of making the best treatment decisions.

Individual patients drew me into the field of hematology/oncology. I am driven by the desire to develop better, less toxic treatments for our lymphoma and leukemia patients. I also have an amazing team working with me that is focused on communicating with and educating our patients, helping them in every aspect of their lives.

If I were to recommend one thing to patients, it would be to ask about clinical trials. While a clinical trial may not be appropriate in every circumstance, all patients should learn about these important options.

Conditions I Treat

- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Chronic lymphocytic leukemia



MD | Northeastern Ohio Universities College of Medicine — 2000

Post-doctoral Training & Residency:

Fellowship in Hematology/Oncology at University Hospitals of Cleveland — 2004 - 2007
Internship in Internal Medicine at University Hospitals of Cleveland — 2000 - 2001
Residency in Internal Medicine at University Hospitals of Cleveland — 2001 - 2003


Paul M. Barr, M.D. is an Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute.

Dr. Barr received his medical degree from Northeast Ohio Medical University. His postgraduate training included an internship, residency and chief residency at Case Western Reserve University. He subsequently completed a hematology and oncology fellowship at Case Western and now holds subspecialty certification in Internal Medicine, Hematology and Oncology.

He is a member of the lymphoma committee in the Southwest Oncology Group and serves as principal investigator on several local and national clinical trial treatment protocols for chronic lymphocytic leukemia and non-Hodgkin lymphoma.

His research interests focus on the development of novel therapeutics for patients with chronic lymphocytic leukemia and lymphoma. He has received a NIH funded K12 award during his training for his work with the organic amine Methoxyamine to improve the effect of fludarabine for CLL patients. Most recently, he was awarded a Clinical Research award from the Lymphoma Research Foundation based o his work developing combination therapies targeting molecules within the B cell receptor pathway for CLL and lymphoma patients.


Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, Hodgson D, Ricardi U, Hoppe RT, Advani R, Mauch PM, Constine LS, Specht L, Li Y, Terezakis SA, Wirth A, Reinartz G, Eich HT, Aleman BMP, Barr P, Yahalom J. "Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)." Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Sep 1; 28(9):2185-2190.

Rowswell-Turner RB, Barr PM. "Treatment of chronic lymphocytic leukemia in older adults." Journal of geriatric oncology.. 2017 Sep 0; 8(5):315-319. Epub 2017 May 06.

Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C, Gupta N, Janelsins MC, Barr PM, Zent CS. "Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies." Leukemia & lymphoma.. 2017 Jul 11; :1-8. Epub 2017 Jul 11.

View All Publications